Drug development platform creator Xbiome has raised nearly $100m in series B funding while bioindustrial startup services provider 21st.Bio secured a similar amount from Novo.
Funding
Xbiome, the China-based creator of an artificial intelligence-equipped drug development platform, has raised almost $100m in a series B round featuring Legend Capital, the venture capital firm established by conglomerate Legend Holdings. It was joined in the round by 5Y Capital, Primavera Capital, Gaorong Capital and Hike Capital.
Pharmaceutical firm Novo has provided €86m ($97.2m) in funding for 21st.Bio, a Denmark-based provider of scale-up services for bioindustrial startups. The company has also licensed technology from bioinnovation technology producer Novozymes.
NASN Automotive Electronics, a China-based developer of control systems for intelligent vehicles, has completed a RMB500m ($78.5m) series C round that included advanced battery producer Contemporary Amperex Technology. The round also featured Bank of China Group Investment, a vehicle for financial services firm Bank of China, as well as Hillhouse Capital’s GL Ventures unit and CMC-SDIC Capital.
Avoma, the US-based developer of an artificial intelligence-equipped meeting assistant, has secured $12m…
